

# Hong Lu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3893104/publications.pdf>

Version: 2024-02-01

59  
papers

2,965  
citations

218677

26  
h-index

175258

52  
g-index

62  
all docs

62  
docs citations

62  
times ranked

2122  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Association of Trefoil Factors with Gastric Cancer and Premalignant Lesions: A Cross-Sectional Population-Based Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 625-632.	2.5	2
2	E-Test or Agar Dilution for Metronidazole Susceptibility Testing of <i>Helicobacter pylori</i> : Importance of the Prevalence of Metronidazole Resistance. <i>Frontiers in Microbiology</i> , 2022, 13, 801537.	3.5	2
3	Chinese Consensus Report on Family-Based <i>Helicobacter pylori</i> Infection Control and Management (2021 Edition). <i>Gut</i> , 2022, 71, 238-253.	12.1	81
4	Susceptibility testing alone will not reliably achieve high <i>Helicobacter pylori</i> cure rates: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, , .	2.8	1
5	Primary Antibiotic Resistance of <i>Helicobacter pylori</i> in Different Regions of China: A Systematic Review and Meta-Analysis. <i>Pathogens</i> , 2022, 11, 786.	2.8	24
6	Vonoprazan-containing <i>Helicobacter pylori</i> triple therapies contribution to global antimicrobial resistance. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1159-1163.	2.8	47
7	Prevalence and associated risk factors of <i>Helicobacter pylori</i> infection in the Wuwei cohort of northwestern China. <i>Tropical Medicine and International Health</i> , 2021, 26, 290-300.	2.3	22
8	Peptidomics analysis revealed that a novel peptide VMP19 protects against AngII-induced injury in human umbilical vein endothelial cells. <i>Molecular Medicine Reports</i> , 2021, 23, .	2.4	2
9	The prevalence of <i>Helicobacter pylori</i> infection in inflammatory bowel disease in China: A case-control study. <i>PLoS ONE</i> , 2021, 16, e0248427.	2.5	9
10	Lessons learned from upper gastrointestinal endoscopy in asymptomatic Chinese. <i>Helicobacter</i> , 2021, 26, e12803.	3.5	5
11	Time trends in the prevalence of <i>Helicobacter pylori</i> infection in patients with peptic ulcer disease: a single-center retrospective study in Shanghai. <i>Journal of International Medical Research</i> , 2021, 49, 030006052110511.	1.0	1
12	Age is the only predictor for upper gastrointestinal malignancy in Chinese patients with uncomplicated dyspepsia: a prospective investigation of endoscopic findings. <i>BMC Gastroenterology</i> , 2021, 21, 441.	2.0	1
13	<i>Helicobacter pylori</i> diagnosis and therapy in the era of antimicrobial stewardship. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110640.	3.2	28
14	Screening and eradication of <i>Helicobacter pylori</i> for gastric cancer prevention: the Taipei global consensus. <i>Gut</i> , 2020, 69, 2093-2112.	12.1	239
15	Downregulation of MEG3 promotes neuroblastoma development through FOXO1-mediated autophagy and mTOR-mediated epithelial-mesenchymal transition. <i>International Journal of Biological Sciences</i> , 2020, 16, 3050-3061.	6.4	19
16	Susceptibility-guided therapy for <i>Helicobacter pylori</i> infected penicillin-allergic patients: A prospective clinical trial of first-line and rescue therapies. <i>Helicobacter</i> , 2020, 25, e12699.	3.5	14
17	Analysis of by high-throughput sequencing: <i>Helicobacter pylori</i> infection and salivary microbiome. <i>BMC Oral Health</i> , 2020, 20, 84.	2.3	24
18	14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line <i>Helicobacter pylori</i> Treatment. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3639-3646.	2.3	16

#	ARTICLE	IF	CITATIONS
19	PPI+amoxicillin dual therapy for <i>Helicobacter pylori</i> infection: An update based on a systematic review and meta-analysis. <i>Helicobacter</i> , 2020, 25, e12692.	3.5	58
20	Editorial: not yet time for universal susceptibility-guided first-line <i>Helicobacter pylori</i> treatment—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 332-332.	3.7	0
21	Management of <i>Helicobacter pylori</i> infection by clinicians: A nationwide survey in a developing country. <i>Helicobacter</i> , 2019, 24, e12656.	3.5	14
22	Susceptibility-guided therapy for <i>Helicobacter pylori</i> infection treatment failures. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481987492.	3.2	27
23	Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing <i>Helicobacter pylori</i> -associated diseases. <i>Helicobacter</i> , 2019, 24, e12563.	3.5	33
24	High-dose PPI+amoxicillin dual therapy with or without bismuth for first-line <i>Helicobacter pylori</i> therapy: A randomized trial. <i>Helicobacter</i> , 2019, 24, e12596.	3.5	52
25	Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line <i>Helicobacter pylori</i> treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1385-1394.	3.7	79
26	Relative potency of proton-pump inhibitors, <i>Helicobacter pylori</i> therapy cure rates, and meaning of double-dose PPI. <i>Helicobacter</i> , 2019, 24, e12554.	3.5	61
27	Multiple balloon-like lesions in the small intestine of an adult with chronic diarrhoea. <i>Gut</i> , 2019, 68, 452-452.	12.1	0
28	Fifth Chinese National Consensus Report on the management of <i>Helicobacter pylori</i> infection. <i>Helicobacter</i> , 2018, 23, e12475.	3.5	304
29	Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple <i>Helicobacter pylori</i> therapy despite a high prevalence of antimicrobial resistance. <i>Helicobacter</i> , 2018, 23, e12485.	3.5	39
30	Inappropriate treatment in <i>Helicobacter pylori</i> eradication failure: a retrospective study. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 130-133.	1.5	30
31	Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for <i>Helicobacter pylori</i> Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	27
32	Furazolidone-containing triple and quadruple eradication therapy for initial treatment for <i>Helicobacter pylori</i> infection: A multicenter randomized controlled trial in China. <i>Helicobacter</i> , 2018, 23, e12496.	3.5	17
33	Understanding treatment guidelines with bismuth and non-bismuth quadruple <i>Helicobacter pylori</i> eradication therapies. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 679-687.	4.4	55
34	Meta-analysis: High-dose vs. low-dose metronidazole-containing therapies for <i>Helicobacter pylori</i> eradication treatment. <i>PLoS ONE</i> , 2018, 13, e0189888.	2.5	23
35	Primary antibiotic resistance in <i>Helicobacter pylori</i> in the Asia-Pacific region: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 707-715.	8.1	238
36	Treating <i>Helicobacter pylori</i> effectively while minimizing misuse of antibiotics. <i>Cleveland Clinic Journal of Medicine</i> , 2017, 84, 310-318.	1.3	53

#	ARTICLE	IF	CITATIONS
37	Failure of optimized dual proton pump inhibitor amoxicillin therapy: What now?. Saudi Journal of Gastroenterology, 2017, 23, 265.	1.1	20
38	Kyoto global consensus report on <i>Helicobacter pylori</i> gastritis and its impact on Chinese clinical practice. Journal of Digestive Diseases, 2016, 17, 353-356.	1.5	5
39	Efficacy and safety of high-dose dual therapy for <i>Helicobacter pylori</i> rescue therapy: A systematic review and meta-analysis. Journal of Digestive Diseases, 2016, 17, 811-819.	1.5	33
40	Combined effects of elevated temperature and CO <sub>2</sub> concentration on Cd and Zn accumulation dynamics in <i>Triticum aestivum</i> L.. Journal of Environmental Sciences, 2016, 47, 109-119.	6.1	9
41	Embelin and Its Role in Chronic Diseases. Advances in Experimental Medicine and Biology, 2016, 928, 397-418.	1.6	22
42	Rescue Therapy for <i>Helicobacter pylori</i> Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy. American Journal of Gastroenterology, 2016, 111, 1736-1742.	0.4	70
43	Role of bismuth in improving <i>Helicobacter pylori</i> eradication with triple therapy. Gut, 2016, 65, 870-878.	12.1	197
44	Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line <i>Helicobacter pylori</i> therapy. Gut, 2015, 64, 1715-1720.	12.1	129
45	New dual therapy for primary treatment of <i>Helicobacter pylori</i> infection: A prospective randomized study in Shanghai, China. Journal of Digestive Diseases, 2014, 15, 622-627.	1.5	26
46	Efficacy of Bismuth-Containing Quadruple Therapies for Clarithromycin-, Metronidazole-, and Fluoroquinolone-Resistant <i>Helicobacter pylori</i> Infections in a Prospective Study. Clinical Gastroenterology and Hepatology, 2013, 11, 802-807.e1.	4.4	140
47	Bismuth-containing quadruple therapy for <i>Helicobacter pylori</i> . European Journal of Gastroenterology and Hepatology, 2013, 25, 1.	1.6	56
48	High Efficacy of 14-Day Triple Therapy-Based, Bismuth-Containing Quadruple Therapy for Initial <i>Helicobacter pylori</i> Eradication. Helicobacter, 2010, 15, 233-238.	3.5	108
49	Efficient differentiation of newly derived human embryonic stem cells from discarded blastocysts into hepatocyte-like cells. Journal of Digestive Diseases, 2010, 11, 376-382.	1.5	7
50	Resistance of <i>Helicobacter pylori</i> to antibiotics from 2000 to 2009 in Shanghai. World Journal of Gastroenterology, 2010, 16, 5118.	3.3	65
51	African, Asian or Indian enigma, the East Asian <i>Helicobacter pylori</i> : facts or medical myths. Journal of Digestive Diseases, 2009, 10, 77-84.	1.5	66
52	The <i>Helicobacter pylori</i> duodenal ulcer promoting gene, dupA in China. BMC Gastroenterology, 2008, 8, 49.	2.0	63
53	Duodenal ulcer promoting gene of <i>Helicobacter pylori</i> . Gastroenterology, 2005, 128, 833-848.	1.3	264
54	Effect of <i>Helicobacter pylori</i> infection on cyclooxygenase-2 expression in gastric antral mucosa. Chinese Journal of Digestive Diseases, 2002, 3, 75-78.	1.0	1

#	ARTICLE	IF	CITATIONS
55	Multicenter randomized controlled trial of heat-killed <i>Lactobacillus acidophilus</i> LB in patients with chronic diarrhea. Chinese Journal of Digestive Diseases, 2002, 3, 167-171.	1.0	8
56	Expression of cyclooxygenase-2 protein in colon disease. Chinese Journal of Digestive Diseases, 2001, 2, 150-154.	1.0	0
57	A new quadruple therapy for <i>Helicobacter pylori</i> using tripotassium dicitrato bismuthate, furazolidone, josamycin and famotidine. Alimentary Pharmacology and Therapeutics, 2000, 14, 1519-1522.	3.7	22
58	Consensus on Quality Indicators for Pediatric Oncology Nursing Care in Mainland China: A Delphi Method and Analytic Hierarchy Process. , 0, , 275275302110687.		0
59	Both family-based <i>Helicobacter pylori</i> infection control and management strategy and screen-and-treat strategy are cost-effective for gastric cancer prevention. <i>Helicobacter</i> , 0, , .	3.5	6